Key information

🔎 Fund Overview

Nuvation Bio Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes mechanistically distinct oncology therapeutic product candidates, each targeting some of the difficult-to-treat types of cancer. The Company’s clinical-stage product candidate, NUV-868, is a BD2-selective oral small molecule bromodomain and extra terminal (BET) inhibitor. NUV-868 inhibits the protein BRD4, a member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. It has designed NUV-868 to reduce the therapeutic limiting toxicities of BRD4 inhibitors in development by optimizing BD2 versus BD1 selectivity. Its drug-drug conjugate (DDC) platform is a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).